You are viewing the site in preview mode
Skip to main content
| |
PAF (n = 127)
|
PerAF (n = 231)
|
p-value
|
|---|
|
Basic characteristics
|
|
Age (years)
|
80 (73–84)
|
79 (73–84)
|
0.94
|
|
Male gender
|
66 (52%)
|
128 (55%)
|
0.53
|
|
BMI (kg/m2)
|
22.6 (20.6–24.9)
|
22.5 (20.5–25.2)
|
0.73
|
|
Risk stratification
|
|
CHADS2 score
|
3 (2–4)
|
3 (2–4)
|
< 0.0001
|
|
CHA2DS2-VASc score
|
4 (3–5)
|
5 (4–6)
|
< 0.0001
|
|
HAS-BLED score
|
3 (2–3)
|
3 (2–4)
|
0.0004
|
|
Congestive heart failure
|
32 (25%)
|
92 (40%)
|
0.005
|
|
Hypertension
|
95 (75%)
|
180 (78%)
|
0.52
|
|
Diabetes mellitus
|
27 (21%)
|
80 (35%)
|
0.008
|
|
Prior cerebral infarction or TIA
|
45 (35%)
|
121 (52%)
|
0.003
|
|
Vascular disease
|
23 (18%)
|
63 (27%)
|
0.05
|
|
Antiplatelet use
|
26 (20%)
|
54 (23%)
|
0.60
|
|
Smoking
|
14 (11%)
|
32 (14%)
|
0.51
|
|
Dyslipidemia
|
78 (61%)
|
140 (61%)
|
0.91
|
|
Blood chemistry
|
|
Cre (mg/dL)
|
0.83 (0.72–0.99)
|
0.85 (0.71–1.11)
|
0.32
|
|
CCr (mL/min)
|
51.6 (38.8–65.2)
|
50.3 (37.3–66.7)
|
0.83
|
|
PT-INR
|
0.99 (0.92–1.05)
|
1.04 (0.96–1.15)
|
< 0.0001
|
|
Treatment
|
|
rt-PA thrombolysis
|
22 (17%)
|
33 (14%)
|
0.45
|
|
OAC before onset
| | |
< 0.0001
|
|
None
|
110 (87%)
|
145 (63%)
| |
|
WF
|
11 (9%)
|
72 (31%)
| |
|
DOAC
|
6 (5%)
|
14 (6%)
| |
- Data are shown as median (25th–75th percentiles) or n (%). Creatinine clearance was estimated by the Cockcroft-Gault equation. PAF indicates paroxysmal atrial fibrillation, PerAF persistent or permanent atrial fibrillation, BMI; body mass index, TIA; transient ischemic attack, Cre serum creatinine, CCr creatinine clearance, PT-INR prothrombin time-international normalized ratio, rt-PA recombinant tissue plasminogen activator, OAC oral anticoagulant, WF warfarin, DOAC direct oral anticoagulant
